A review of monoclonal antibody therapies in lymphoma

Critical Reviews in Oncology/hematology
Esmeralda Chi-Yuan TeoColin Phipps

Abstract

Monoclonal antibodies (moAb) represent a novel way of delivering therapy through specific target antigens expressed on lymphoma cells and minimizes the collateral damage that is common with conventional chemotherapy. The paradigm of this approach is the targeting of CD20 by rituximab. Since its FDA approval in 1997, rituximab has become the standard of care in almost every line of therapy in most B-cell lymphomas. This review will briefly highlight some of the key rituximab trials while looking more closely at the evidence that is bringing other antibodies, including next generation anti-CD20 moAbs, and anti-CD30 moAbs, among others to the forefront of lymphoma therapy.

References

Mar 4, 1982·The New England Journal of Medicine·R A MillerR Levy
Sep 9, 1982·The New England Journal of Medicine·K A Foon
Sep 1, 1994·Immunology Today·T F Tedder, P Engel
Feb 1, 1997·Current Biology : CB·L NitschkeM C Lamers
Jul 28, 2001·The New England Journal of Medicine·R J KreitmanI Pastan
Jan 25, 2002·The New England Journal of Medicine·Bertrand CoiffierChristian Gisselbrecht
Jun 5, 2003·Nature Biotechnology·Svetlana O DoroninaPeter D Senter
Sep 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anas Younes, Marshall E Kadin
Aug 3, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J KreitmanIra Pastan
Sep 8, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas ElterAndreas Engert
Jun 27, 2006·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Tomoko WatanabeIsao Serizawa
Nov 7, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter HillmenJiri Mayer
Oct 16, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Franck MorschhauserAnton Hagenbeek
May 27, 2009·British Journal of Haematology·Andres Forero-TorresAjay K Gopal
Oct 28, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lindsey GoffAma Rohatiner
Jan 21, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Nicole M OkeleyStephen C Alley
Mar 3, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·William G WierdaUNKNOWN Hx-CD20-406 Study Investigators
Mar 31, 2010·Seminars in Hematology·Stephen A BeersMartin J Glennie

❮ Previous
Next ❯

Citations

Nov 15, 2015·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Harry AlexopoulosMarinos C Dalakas
Aug 1, 2016·Current Hematologic Malignancy Reports·Marco Ruella, Carl H June
Jan 25, 2017·Expert Review of Hematology·Annamaria BrioliMarie Von Lilienfeld-Toal
Oct 11, 2017·Angewandte Chemie·Steffen DaumAndriy Mokhir
Jul 24, 2018·Angewandte Chemie·Viktor ReshetnikovAndriy Mokhir
Dec 18, 2019·Current Medical Science·Xin YangJian-Feng Zhou
Jul 12, 2017·Drug Development and Industrial Pharmacy·Amir Hossein Mohammad ZadehKambiz Gilani
Mar 16, 2017·Frontiers in Plant Science·Qian ShiHong Ma
Jan 13, 2018·Expert Opinion on Investigational Drugs·Magdalena WitkowskaTadeusz Robak
May 2, 2019·Cancer Discovery·Chen LossosDavid M Weinstock
Nov 19, 2020·Journal of Controlled Release : Official Journal of the Controlled Release Society·Marie RütterAyelet David

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Related Papers

The New England Journal of Medicine
Daniel El FassiClaus H Nielsen
The New England Journal of Medicine
Ronald P TaylorClive S Zent
The New England Journal of Medicine
Andrea CalcagnoGiovanni Di Perri
The New England Journal of Medicine
D G Maloney
© 2021 Meta ULC. All rights reserved